

Form PTO-1449 (modified)

Atty. Docket No.  
4100.001099Serial No.  
10/796,782

List of Patents and Publications for Applicant's

Applicant  
Brewer *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
March 09, 2004Group:  
1616U.S. Patent Documents  
See Page 1-2Foreign Patent Documents  
See Page 2Other Art  
See Page 2-7

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A16	5,112,598	05/12/92	Biesalski	424		
	A17	5,527,533	06/18/96	Tso <i>et al.</i>	424		
	A18	5,556,611	09/17/96	Biesalski	424		
	A19	5,583,153	12/10/96	Brahn	514		
	A20	5,970,974	10/26/99	Van der Linden <i>et al.</i>	128		
	A21	5,954,047	09/21/99	Armer <i>et al.</i>	128		
	A22	5,950,619	09/14/99	van der Linden <i>et al.</i>	128		
	A23	5,698,155	12/16/97	Grosswald <i>et al.</i>	264		
	A24	5,639,725	06/17/97	O'Reilly <i>et al.</i>	514		
	A25	4,765,539	08/23/88	Noakes <i>et al.</i>	239		
	A26	3,916,899	11/04/75	Theeuwes <i>et al.</i>	128		
	A27	3,845,770	11/05/74	Theeuwes <i>et al.</i>	128		
	A28	4,604,278	08/05/86	Reilly <i>et al.</i>	423		
	A29	4,343,746	08/10/82	Anglin <i>et al.</i>	556		
	A30	2,909,541	10/20/59	Hugel	260		
	A31	6,703,050	03/09/04	Brewer <i>et al.</i>	424		
	A32	5,639,757	June 17, 1997	Dow <i>et al.</i>	514	261	
	A33	5,712,291	Jan. 27, 1998	D'Amato	514	323	
	A34	5,753,230	May 19, 1998	Brooks <i>et al.</i>	424	158.1	
	A35	5,972,922	Oct. 26, 1999	Wilks <i>et al.</i>	514	178	

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A36	2004/0009237 A1	Jan. 15, 2004	Brewer	424	617	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 1 107 795 B1	Nov. 27, 2002	EP			
	B2	EP 1 234 585 A2	Aug. 28, 2002	EP			
	B3	WO 00/13712	Mar. 16, 2000	PCT			
	B4	WO 2004/009072	Jan. 29, 2004	PCT			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C83	Benjamin <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C84	Borgstrom <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>In Vivo</i> ," <i>The Prostate</i> , 35:1-10, 1998.
	C85	Jeannin <i>et al.</i> , "Molecular Architecture of Copper(1) Thiometallate Complexes. Examples of a Cubane with an Extra Face, (NPr <sub>4</sub> ) <sub>3</sub> [MS <sub>4</sub> Cu <sub>4</sub> Cl <sub>5</sub> ]," <i>Inorganic. Chimica. Acta.</i> , 198-200:493-500, 1992.
	C86	Malavé <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngenic Mice," <i>J. Natl. Cancer Inst.</i> , 62(1):83-88, 1979.
	C87	Passaniti <i>et al.</i> , "Methods in Laboratory Investigation," <i>Laboratory Investigation</i> , 67(4):519-528, 1992.
	C88	Sécheresse <i>et al.</i> , "Heterobimetallic Aggregates of Copper(1) with Thio-tungstate and -molybdate. Cation Effect in Aggregation of Ms <sub>4</sub> Cu <sub>4</sub> Cl <sub>5</sub> Units, a Crystallographic Study," <i>J. Chem. Soc. Dalton Trans.</i> , 11:2875-2881, 1991.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C89	Sugiura <i>et al.</i> , "Studies in a Tumor Spectrum," <i>Cancer Research</i> , 15:38-51, 1955.
	C90	Takai <i>et al.</i> , "Preparation, Structure and Properties of Mixed-Metal Trinuclear Complex: (Pr <sub>4</sub> N) <sub>2</sub> [MoO(WS <sub>4</sub> ) <sub>2</sub> ]," <i>Chemistry Letters</i> , 8:645-646, 1996.
	C91	Bajou <i>et al.</i> , "Absence of Host Plasminogen Activator Inhibitor I Prevents Cancer Invasion and Vascularization," <i>Nat. Med.</i> , 4:923-928, 1998.
	C92	Bamba <i>et al.</i> , "Release Mechanisms in Gel Forming Sustained Release Preparations," <i>Int. J. Pharm.</i> , 2:307, 1979.
	C93	Blood <i>et al.</i> , "Tumor Interactions With the Vasculature: Angiogenesis and Tumor Metastasis", <i>Biochim. Biophys. Acta.</i> , 1032:89-118, 1990.
	C94	Brown, "Metal Toxicity and Therapeutic Intervention," <i>Biochem. Soc. Trans.</i> , 30:742- 745 2002.
	C95	Brown, "Copper and Prion Disease," <i>Brain Res. Bull.</i> , 55:165-173, 2001.
	C96	Carri <i>et al.</i> , "Copper-Dependent Oxidative Stress, Alteration of Signal Transduction and Neurodegeneration in Amyotrophic Lateral Sclerosis," <i>Funct. Neurol.</i> , 16:181-188, 2001.
	C97	Chakravarty <i>et al.</i> , "Serum Copper in Malignant Neoplasia with Special Reference to the Cervix Uteri," <i>J. Cancer Res. Clin. Oncol.</i> , 108: 312-315, 1984.
	C98	Chambers <i>et al.</i> , "Macrophage Colony-Stimulating Factor Mediates Invasion of Ovarian Cancer Cells Through Urokinase," <i>Cancer Research</i> , 55:1578-1585, 1995.
	C99	Chen <i>et al.</i> , "TNF-RI Signaling: A Beautiful Pathway," <i>Science</i> , 296:1634-1635, 2002.
	C100	Crowley <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> , 90:5021-5025, 1993.
	C101	During <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant; In vivo Characterization," <i>Ann. Neurol.</i> , 25:351-356, 1989.
	C102	Folkman, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> , 175: 409-416, 1972.
	C103	Folkman, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> , 1(2):120-122 1995.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C104	Gnjec <i>et al.</i> , "Transition Metal Chelator Therapy - A potential Treatment For Alzheimer's Disease?" <i>Front Biosci.</i> , 16-23, 2002.
	C105	Goodson, "Medical Applications of Controlled Release" 2:115-138, 1984.
	C106	Gorelik <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l. Cancer Inst.</i> , 65: 1257-1264, 1980.
	C107	Gorelik, <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control-Progression of Postoperative Lung Metastasis," <i>Rec. Results Cancer Res.</i> , 75:20-28, 1980.
	C108	Hanada <i>et al.</i> , "Regulation of Cytokine Signaling and Inflammation," <i>Cytokine Growth Factor Rev.</i> , 13: 413-421, 2002.
	C109	Hanahan <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):355-364, 1996.
	C110	Hilgard <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> , 35:78-86, 1977.
	C111	Howard <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," <i>J. Neurosurg.</i> , 71:105-112, 1989.
	C112	Isakov <i>et al.</i> , "An Immune Response Against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Metas.</i> , 2:12-32, 1982.
	C113	Kleinman <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochem.</i> , 25: 312-318, 1986.
	C114	Koch <i>et al.</i> , "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis," <i>Science</i> , 258:1798-1801, 1992.
	C115	Kowalik-Jankowska <i>et al.</i> , "Possible Involvement of Copper (II) in Alzheimer Disease," <i>Environ. Health Perspect.</i> , 5:869-870, 2002.
	C116	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> , 23:61-126, 1983.
	C117	Langer, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1533, 1990.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C118	Levy <i>et al.</i> , Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> , 228:190-192, 1985.
	C119	Llanos <i>et al.</i> , "The Molecular Basis of Copper Homeostasis and Copper-Related Disorders," <i>DNA Cell Biol.</i> , 21:259-270, 2002.
	C120	Loskutoff <i>et al.</i> , "A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM," <i>Ann. N.Y. Acad. Sci.</i> , 902:272-282, 2000.
	C121	Malave <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Cancer Inst.</i> , 62:83-88, 1979.
	C122	Mandinov <i>et al.</i> , "Copper Chelation Represses the Vascular Response To Injury" <i>PNAS</i> , 100:6700-6705, 2003.
	C123	Maynard <i>et al.</i> , "Overexpression of Alzheimer's Disease Amyloid- $\beta$ Opposes the Age-Dependent Elevations of Brain Copper and Iron," <i>J. Biol. Chem.</i> , 277(47):44670-44676, 2002.
	C124	Millauer <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>In vivo</i> ," <i>Cancer Res.</i> , 56:1615-1620, 1996.
	C125	Min <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , 56:2428-2433, 1996.
	C126	Miyake <i>et al.</i> , "Transforming Growth Factor- $\beta$ 1 Stimulates Contraction of Human Glioblastoma Cell-Mediated Collagen Lattice Through Enhanced $\alpha$ 2 Integrin Expression," <i>J. Neuropathol. Exp. Neurol.</i> , 59:18-28, 2000.
	C127	Nguyen <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> , 47:31-40, 1994.
	C128	Odedra <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> , 49:111-124, 1991.
	C129	Osawa <i>et al.</i> , "Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF- $\kappa$ B and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes," <i>Infect. Immun.</i> , 70:6294-6301, 2002.
	C130	Pan <i>et al.</i> , "Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis," <i>Cancer Res.</i> , 62: 4854-4859, 2002.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C131	Parish <i>et al.</i> , "A Basement-Membrane Permeability Assay Which Correlates with the Metastatic Potential of Tumor Cells," <i>Int. J. Cancer</i> , 52:378-383, 1992.
	C132	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea" <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C133	Passaniti <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab. Invest.</i> , 67:519-528, 1992.
	C134	Patstone <i>et al.</i> , "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271(7):3343-3346, 1996.
	C135	Perry <i>et al.</i> , "The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders," <i>CNS Drugs</i> , 16:339-352, 2002.
	C136	Rabbani <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> By a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)," <i>Int. J. Cancer</i> , 63:840-845, 1995.
	C137	Redman <i>et al.</i> , "Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer," <i>Clin. Cancer Res.</i> , 9:1666-1672, 1996.
	C138	Rupnick <i>et al.</i> , "Adipose Tissue Mass Can Be Regulated Through the Vasculature," <i>Proc. Natl. Acad. Sci.</i> , 99:10730-10735, 2002.
	C139	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 321:574, 1989.
	C140	Schnaper <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , 165:107-118, 1995.
	C141	Sefton, "Implantable Pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , 14(3):201-240, 1987.
	C142	Sen <i>et al.</i> , "Copper-Induced Vascular Endothelial Growth Factor Expression and Wound Healing," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:H1821-H1827, 2002.
	C143	Shockley <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> , 617:367-382, 1991.
	C144	Strausak <i>et al.</i> , "Copper in Disorders with Neurological Symptoms: Alzheimer's, Menkes, and Wilson Diseases," <i>Brain Res. Bull.</i> , 55:175-185, 2001.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C145	Talmadge <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Cancer Inst.</i> , 69:975-980, 1982
	C146	Thakur <i>et al.</i> , "Indium-111-Labeled Leukocytes for the Localization of Abscesses: Preparation, Analysis, Tissue Distribution, and Comparison with Gallium-67 Citrate in Dogs," <i>J. Lab. Clin. Med.</i> , 89:217-228, 1977.
	C147	Treat <i>et al.</i> , in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, 353-365, 1989.
	C148	Van Golen <i>et al.</i> , "Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma," <i>Neoplasia</i> , 4(5):373-379, 2002.
	C149	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Develop. Indus. Pharm.</i> , 26(7):665-708, 2000.
	C150	Verscheyie <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 80, Suppl. 2, 96, 1999.
	C151	Volpert <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> , 98:671-679, 1996.
	C152	Xing <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> , 67:423-429, 1996.
	C153	International Search Report for PCT/US03/003210, mailed December 18, 2003 (4100.003210).
	C154	International Search Report for PCT/US03/23031, mailed June 29, 2004

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

EXAMINER: /Leigh Maier/	DATE CONSIDERED: 05/30/2008
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	